Lars Zeepvat
Founder & CEO
BS Accounting, Penn State Smeal. Built Bardel from his mother's pain, connecting clinical, cardiac, and CMS into one platform. Leads vision and scale.
The team
The people building the future of medicine.
A founder whose own family lived the problem, a CTO out of AWS and Capital One, a CFA-credentialed CFO, and a Chief Science Officer with 45 publications, advised by leaders who managed four million Medicare patients, launched a category-defining drug, and spent careers in pain medicine and molecular science.
Leadership
A team built to make medicine measurable.
Deep clinical and scientific credentials paired with operators who have shipped, scaled, and exited before. The people turning the measurement layer of medicine from an idea into infrastructure.
6
Leaders across clinical, science, finance, and growth
70+
Combined years our leadership scientists have spent in molecular science and clinical pharmacology
2
Penn State engineering founders behind the platform
Dr. Jose Walewski
Chief Science Officer
Cornell PhD, Mount Sinai Pulmonary. 45 publications and 1,750+ citations. Co-inventor of two US-patented therapies. Guides pharmacology and evidence.
Will Houston
Chief Financial Officer
CFA, Duke. Led finance at Keriton through its acquisition by Natus Medical. Built Bardel's RTM billing infrastructure.
Frederick Sion
Co-Founder & CTO
BS Computer Science, Penn State. Ex-Amazon AWS, ex-Capital One. Built the real-time clinical intelligence and CMS documentation platform.
Aditya Khetarpal
Director of Software Engineering
MS Computer Science, AI and ML. Built the AI cardiac analytics engine and reduced infrastructure API costs by 90%.
Gavin Pettigrew
VP Hardware
BS Mechanical Engineering. Designed the Bardel platform end to end: $25 BOM, 83% margin, 21-day battery life.
Clinical & Operational Advisors
People who have already built what we are building toward.
Clinical, payer, pharma, device, and capital-markets leaders who shape the strategy. Each is named with the real credential they bring, from managing four million Medicare patients to launching a category-defining drug to four decades in pain medicine.
Nancy G. Cocozza
Medicare & Payer Strategy
Former President of Medicare at Aetna, where she managed 4 million Medicare patients. Validates Bardel's RTM and CMS reimbursement strategy.
Jeremy Shepler
Pharma Launch Strategy
Former VP, Global Commercial, at Johnson & Johnson. Launched Ozempic at Novo Nordisk. Advises on phased deployment and the pharma roadmap.
Dr. Karyemaitre Aliffe
Biomedical Advisor
Harvard- and Stanford-trained MD-PhD with 35+ years in clinical research. Designed the BARDEL-001 trial methodology and cardiac phenotype framework.
Dr. Brian Shaffer
Chronic Pain Trials
Founder of Princeton Pain Management. Leading the 100-patient opioid-sparing cohort.
Jeanette Numbers, IDSA
Medical Device Design
Nova Design Group. Led device programs for Teva, 3M, and Samsung. Guides Bardel through FDA design controls.
Donald Ballai
Healthcare Capital Markets
CEO of South Lane Wealth Management with 40 years in MedTech capital markets. Drives institutional partnerships and go-to-market.
Build the future of medicine with us
A team this deep is a signal in itself.
Explore a partnership, or take a closer look at the round.